The development of next-generation drug-based approaches to treat inner ear disorders is gaining momentum, with multiple INDs approved in the last six months and big pharma making plays to acquire innovative biotechs working on hearing loss.

However, in a space that has also had to battle with multiple clinical failures, there’s a genuine need for the industry to unite and overcome the specific obstacles that are currently acting as a barrier to late-stage clinical trials and through to approval.

That’s why the 3rd Inner Ear Disorders Therapeutics Summit is back this summer, bringing together the community to collectively accelerate development of drug-based approaches, sharing case studies and data-driven insights into optimizing preclinical programs and designing translational studies to ultimately validate clinically relevant targets.

This meeting will leverage the latest biotech and academic innovation alongside big pharma experience to address the technical and strategic challenges in delivering a safe and effective therapy to the inner ear.

What to expect from the 2023 meeting:

• Explore how to improve clinical trial design to increase the number of clinical trials achieving regulatory approval
• Delve into the numerous delivery methods being employed in industry and explore how to optimize delivery to the inner ear
• Evaluate the current opportunities and limitations of using animal models to accurately predict preclinical efficacy and translational success
• Leverage valuable insights from VC investors to understand the key considerations made when investing in or forging partnerships with biotechs focussing on inner ear disorder therapeutics
• Navigate the complex landscape of improving the diagnostics of inner ear disorders by developing a robust diagnostic toolbox and strategizing how to supplement patient-reported outcome measures

View the full agenda here: https://ter.li/a2ivra